Macrogenics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 339
- Market Cap
- $215.1M
- Introduction
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Clinical Trials
49
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaClear Cell Adenocarcinoma of OvaryClear Cell Adenocarcinoma of VulvaClear Cell Adenocarcinoma of VaginaClear Cell Adenocarcinoma of CervixClear Cell Adenocarcinoma of UterusClear Cell Adenocarcinoma of Fallopian TubeClear Cell Adenocarcinoma of Peritoneum
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 60
- Registration Number
- NCT06730347
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Ochsner MD Anderson Cancer Center, New Orleans, Louisiana, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study of MGC028 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsNSCLC AdenocarcinomaCholangiocarcinomaPancreatic CarcinomaColorectal Carcinoma
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 124
- Registration Number
- NCT06723236
- Locations
- 🇺🇸
UCSF - Helen Diller Family Cancer Center, San Francisco, California, United States
🇺🇸Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
A Study of MGC026 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and NeckNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerSarcomaEndometrial CancerMelanoma
- Interventions
- Biological: MGC026 Dose EscalationBiological: MGC026 Dose for Expansion
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 250
- Registration Number
- NCT06242470
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Androgen-Independent Prostatic CancerAndrogen-Independent Prostatic NeoplasmsProstate Cancer RecurrentAndrogen-Insensitive Prostatic CanceAndrogen-Resistant Prostatic CancerHormone Refractory Prostatic CancerImmunotherapyImmune Checkpoint InhibitorInhibitory Checkpoint Molecule
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 154
- Registration Number
- NCT05848011
- Locations
- 🇺🇸
United Medical Group, Miami, Florida, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Non-small Cell Lung CancerAndrogen-Independent Prostatic CancerLaryngeal Squamous Cell CarcinomaMelanomaCastration-Resistant Prostatic CancerAndrogen-Insensitive Prostatic CancerHormone Refractory Prostatic CancerAnal CancerAnal NeoplasmHead and Neck Squamous Cell Carcinoma
- Interventions
- Biological: vobramitamab duocarmazine 2.0 mg (Arm A)Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 382
- Registration Number
- NCT05551117
- Locations
- 🇪🇸
Institut Catala d'Oncologia Hospitalet, Barcelona, Spain
🇺🇸Compassionate Cancer Care Medical Group, Fountain Valley, California, United States
🇺🇸University of California Los Angeles (UCLA) Community Cancer Care, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
MacroGenics Names Eric Risser as New CEO, Succeeding 24-Year Leader Scott Koenig
MacroGenics appointed Eric Risser as President and CEO effective August 13, 2025, replacing Scott Koenig who led the company for 24 years.
Specialised Therapeutics Expands Incyte Partnership to Bring Two Novel Cancer Therapies to Asia-Pacific
Specialised Therapeutics has expanded its partnership with Incyte to include axatilimab and retifanlimab for distribution in Australia, New Zealand, and Singapore, with potential expansion to other Asia-Pacific countries.
MacroGenics Secures $70 Million in ZYNYZ Royalty Deal, Extends Cash Runway Through 2027
MacroGenics received a $70 million upfront payment from Sagard Healthcare Partners through a royalty purchase agreement for ZYNYZ, a PD-1 inhibitor approved for anal canal carcinoma and Merkel cell carcinoma.
Akari Therapeutics Appoints Mark F. Kubik to Lead Oncology Business Development for Novel ADC Platform
Akari Therapeutics has appointed Mark F. Kubik as Head of Business Development - Oncology, bringing over 25 years of experience in transformative deal creation across oncology therapeutics.
MacroGenics Faces Shareholder Suit Over Drug Trial Deaths
MacroGenics' officers and directors face a shareholder derivative action alleging breached fiduciary duties after announcing a probe into study participant deaths.
MacroGenics' Vobra Duo Shows Promise in Metastatic Castration-Resistant Prostate Cancer
MacroGenics announced updated Phase 2 TAMARACK study data for vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC).
MacroGenics' Vobra Duo Shows Promise in Metastatic Castration-Resistant Prostate Cancer
MacroGenics announced updated Phase 2 TAMARACK study data, showcasing vobramitamab duocarmazine's (vobra duo) encouraging antitumor activity in metastatic castration-resistant prostate cancer (mCRPC).
MacroGenics' Vobramitamab Duocarmazine Shows Promise in Metastatic Castration-Resistant Prostate Cancer
MacroGenics announced Phase 2 data for vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC) at ESMO 2024.
Byondis Advances Novel HER2-Targeting ADC Trastuzumab Duocarmazine in Multiple Cancer Indications
• Byondis is developing trastuzumab duocarmazine (SYD985), an innovative antibody-drug conjugate targeting HER2, for multiple cancer indications including breast, gastric, and urothelial cancers. • The Dutch pharmaceutical company's lead candidate employs a novel duocarmycin-based HER2-targeting mechanism, expanding treatment options for solid tumors that overexpress HER2. • Byondis is advancing its development program through strategic collaborations with major pharmaceutical companies including Amgen, Allergan, and Macrogenics, alongside academic institutions.
Novel Bispecific Immunotherapy Shows Promise Across Multiple Cancer Types in Early Clinical Trial
A novel bispecific immunotherapy drug, tebotelimab, demonstrated encouraging response rates across multiple advanced cancer types by simultaneously blocking PD-1 and LAG-3 immune checkpoints in a 269-patient international trial.